{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:24:38Z","timestamp":1783398278555,"version":"3.54.6"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kidney Research Yorkshire"},{"name":"Pharmacosmos A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravenous iron is commonly used to treat iron deficiency anemia in non-dialysis chronic kidney disease (ND-CKD). There is a paucity of information on the potential impact of intravenous iron on patient reported outcome measures, functional status and markers of cardiovascular health. As part of the secondary analysis of this double-blind exploratory randomized controlled trial focusing on patients with iron deficiency (+\u2009\/\u2212 anemia) and ND-CKD (serum ferritin\u2009&lt;\u2009200\u00a0\u00b5g\/L or transferrin saturation\u2009\u2264\u200920% and serum ferritin 200\u2013299\u00a0\u00b5g\/L; CKD stages: 3a-5), 26 patients were randomized in a 1:1 ratio to receive ferric derisomaltose or ferric carboxymaltose. Participants received 1000\u00a0mg at baseline and 500\u20131000\u00a0mg at one month to achieve iron repletion. Quality of life and fatigue status were assessed using the Short-Form (36) questionnaire and the fatigue severity scale. Functional status was evaluated using the Duke Activity Status Index and the 1-min-sit-to-stand test. Cardiac markers such as NT-proBNP, Troponin T and pulse wave velocity were monitored. Intravenous iron was associated with similar improvements in most domains of the Short-Form (36) questionnaire, fatigue status, and 1-min-sit-to-stand ability increased significantly by the end of the trial in both groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Markers of cardiac function remained stable, with no arterial stiffness impact. Longer term studies are required to further evaluate the impact of intravenous iron on quality of life and cardiac safety in patients with ND-CKD.<\/jats:p>","DOI":"10.1038\/s41598-023-44578-6","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T20:01:36Z","timestamp":1698350496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD"],"prefix":"10.1038","volume":"13","author":[{"given":"Xenophon","family":"Kassianides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"44578_CR1","doi-asserted-by":"crossref","unstructured":"Palaka, E., Grandy, S., Van Haalen, H., McEwan, P. & Darlington, O. The impact of CKD anaemia on patients: Incidence, risk factors, and clinical outcomes\u2014A systematic literature review. Int. J. Nephrol. 2020, (2020).","DOI":"10.1155\/2020\/7692376"},{"key":"44578_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt, J. L. & Lin, H. Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23, 1631\u20131634 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"44578_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.ajkd.2022.07.014","volume":"81","author":"DK Farrington","year":"2022","unstructured":"Farrington, D. K. et al. Anemia prevalence, type, and associated risks in a cohort of 5.0 million insured patients in the United States by level of kidney function. Am. J. Kidney Diseases 81, 201-209.e1 (2022).","journal-title":"Am. J. Kidney Diseases"},{"key":"44578_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ndt\/gfz192","volume":"36","author":"A Awan","year":"2021","unstructured":"Awan, A. et al. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol. Dial. Transpl. 36, 129\u2013136 (2021).","journal-title":"Nephrol. Dial. Transpl."},{"key":"44578_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2215\/CJN.15360920","volume":"16","author":"ME Cho","year":"2021","unstructured":"Cho, M. E. et al. Heart failure hospitalization risk associated with iron status in veterans with CKD. Clin. J. Am. Soc. Nephrol. 16, 522\u2013531 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"44578_CR6","doi-asserted-by":"publisher","DOI":"10.5837\/bjc.2020.010","author":"X Kassianides","year":"2020","unstructured":"Kassianides, X., Hazara, A. & Bhandari, S. Cardiac complications in end-stage renal disease: A shared care challenge. Br. J. Cardiol. https:\/\/doi.org\/10.5837\/bjc.2020.010 (2020).","journal-title":"Br. J. Cardiol."},{"key":"44578_CR7","doi-asserted-by":"crossref","unstructured":"Wish, J. B. et al. Iron deficiency in CKD without concomitant anemia. Kidney Int. Rep. (2021).","DOI":"10.1016\/j.ekir.2021.07.032"},{"key":"44578_CR8","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","volume":"36","author":"M Guedes","year":"2021","unstructured":"Guedes, M. et al. Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrol. Dialysis Transpl. 36, 1694\u20131703 (2021).","journal-title":"Nephrol. Dialysis Transpl."},{"key":"44578_CR9","doi-asserted-by":"crossref","unstructured":"Finkelstein, F. O., van Nooten, F., Wiklund, I., Trundell, D. & Cella, D. Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health Qual. Life. Outcomes 16, (2018).","DOI":"10.1186\/s12955-018-0933-8"},{"key":"44578_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14814\/phy2.12780","volume":"4","author":"JL Gamboa","year":"2016","unstructured":"Gamboa, J. L. et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol. Rep. 4, 1\u201312 (2016).","journal-title":"Physiol. Rep."},{"key":"44578_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.52586\/4958","volume":"26","author":"S Bhandari","year":"2021","unstructured":"Bhandari, S. Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease. Front. Biosci. - Landmark 26, 442\u2013464 (2021).","journal-title":"Front. Biosci. - Landmark"},{"key":"44578_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U. & Gafter-Gvili, A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: An updated systematic review and meta-analysis. Am. J. Kidney Diseases 68, 677\u2013690 (2016).","journal-title":"Am. J. Kidney Diseases"},{"key":"44578_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007857.PUB3","author":"EL O\u2019Lone","year":"2019","unstructured":"O\u2019Lone, E. L. et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database System. Rev. https:\/\/doi.org\/10.1002\/14651858.CD007857.PUB3 (2019).","journal-title":"Cochrane Database System. Rev."},{"key":"44578_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.amjcard.2020.11.025","volume":"141","author":"M Osman","year":"2021","unstructured":"Osman, M. et al. A meta-analysis of intravenous iron therapy for patients with iron deficiency and heart failure. Am. J. Cardiol. 141, 152 (2021).","journal-title":"Am. J. Cardiol."},{"key":"44578_CR15","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","volume":"42","author":"EA Jankowska","year":"2021","unstructured":"Jankowska, E. A. et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study. Eur. Heart J. 42, 3011 (2021).","journal-title":"Eur. Heart J."},{"key":"44578_CR16","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"17","author":"PR Kalra","year":"2022","unstructured":"Kalra, P. R. et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 17, 2199\u20132209 (2022).","journal-title":"Lancet"},{"key":"44578_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa011","author":"S Bhandari","year":"2020","unstructured":"Bhandari, S. et al. Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dialysis Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfaa011 (2020).","journal-title":"Nephrol. Dialysis Transpl."},{"key":"44578_CR18","doi-asserted-by":"crossref","unstructured":"Zoller, H. et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): A randomised clinical trial. Gut 0, gutjnl-2022-327897 (2022).","DOI":"10.1136\/gutjnl-2022-327897"},{"key":"44578_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2020-11-3","volume":"10","author":"X Kassianides","year":"2021","unstructured":"Kassianides, X. & Bhandari, S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: A narrative review. Drugs Context 10, 1\u201329 (2021).","journal-title":"Drugs Context"},{"key":"44578_CR20","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2020","unstructured":"Schaefer, B. et al. Hypophosphatemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside - A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 87, 2256\u20132273 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"44578_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf, M. et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: Two randomized clinical trials. JAMA \u2013 J. Am. Med. Assoc. 323, 432\u2013443 (2020).","journal-title":"JAMA \u2013 J. Am. Med. Assoc."},{"key":"44578_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000528313","volume":"48","author":"X Kassianides","year":"2023","unstructured":"Kassianides, X. & Bhandari, S. Methodology and baseline data of a comparative exploratory double-blinded randomized study of intravenous iron on fibroblast growth factor 23 and phosphate in chronic kidney disease. Kidney Blood Press Res. 48, 151\u2013164 (2023).","journal-title":"Kidney Blood Press Res."},{"key":"44578_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/PROM.S169653","volume":"9","author":"WE Strauss","year":"2018","unstructured":"Strauss, W. E. & Auerbach, M. Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron. Patient Relat. Outcome Meas. 9, 285 (2018).","journal-title":"Patient Relat. Outcome Meas."},{"key":"44578_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/nhs.12038","volume":"15","author":"A Bonner","year":"2013","unstructured":"Bonner, A., Caltabiano, M. & Berlund, L. Quality of life, fatigue, and activity in Australians with chronic kidney disease: a longitudinal study. Nurs. Health Sci. 15, 360\u2013367 (2013).","journal-title":"Nurs. Health Sci."},{"key":"44578_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/09593985.2018.1455249","volume":"35","author":"TJ Wilkinson","year":"2019","unstructured":"Wilkinson, T. J. et al. Test-retest reliability, validation, and \u2018minimal detectable change\u2019 scores for frequently reported tests of objective physical function in patients with non-dialysis chronic kidney disease. Physiother. Theory Pract. 35, 565\u2013576 (2019).","journal-title":"Physiother. Theory Pract."},{"key":"44578_CR26","doi-asserted-by":"crossref","unstructured":"Bhandari, S., Allgar, V., Lamplugh, A., Macdougall, I. & Kalra, P. A. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol. 22, (2021).","DOI":"10.1186\/s12882-021-02308-y"},{"key":"44578_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jorc.12310","volume":"46","author":"I Hadjiioannou","year":"2020","unstructured":"Hadjiioannou, I. et al. Test-retest reliability for physical function measures in patients with chronic kidney disease. J. Ren. Care 46, 25\u201334 (2020).","journal-title":"J. Ren. Care"},{"key":"44578_CR28","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli, J. E., Lombra\u00f1a, A., Duarte, P. & di Gennaro, F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50, 1657\u20131665 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"44578_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.kint.2016.01.022","volume":"90","author":"RA Zager","year":"2016","unstructured":"Zager, R. A., Johnson, A. C. M. & Frostad, K. B. Combined iron sucrose and protoporphyrin treatment protects against ischemic and toxin-mediated acute renal failure. Kidney Int. 90, 67 (2016).","journal-title":"Kidney Int."},{"key":"44578_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2016.03.039","volume":"212","author":"JE Toblli","year":"2016","unstructured":"Toblli, J. E., Cao, G., Rivas, C., Giani, J. F. & Dominici, F. P. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative\/nitrosative stress and inflammation. Int. J. Cardiol. 212, 84\u201391 (2016).","journal-title":"Int. J. Cardiol."},{"key":"44578_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.23876\/j.krcp.20.120","volume":"40","author":"X Kassianides","year":"2021","unstructured":"Kassianides, X., Gordon, A., Sturmey, R. & Bhandari, S. The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: A randomized controlled pilot study. Kidney Res. Clin. Pract. 40, 89\u201398 (2021).","journal-title":"Kidney Res. Clin. Pract."},{"key":"44578_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-10717-8","volume":"12","author":"X Kassianides","year":"2022","unstructured":"Kassianides, X., Allgar, V., Macdougall, I. C., Kalra, P. A. & Bhandari, S. Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial. Sci. Rep. 12, 1\u20138 (2022).","journal-title":"Sci. Rep."},{"key":"44578_CR33","doi-asserted-by":"crossref","unstructured":"Emrich, I. E. et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose - The randomized controlled HOMe aFers study. BMC Med. 18, (2020).","DOI":"10.1186\/s12916-020-01643-5"},{"key":"44578_CR34","doi-asserted-by":"crossref","unstructured":"Kassianides, X., White, S. & Bhandari, S. Markers of oxidative stress, inflammation and endothelial function following high-dose intravenous iron in patients with non-dialysis-dependent chronic kidney disease-a pooled analysis. Int. J. Mol. Sci. 23, (2022).","DOI":"10.3390\/ijms232416016"},{"key":"44578_CR35","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/j.1523-1755.2005.00754.x","volume":"68","author":"G Schaller","year":"2005","unstructured":"Schaller, G. et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 68, 2814\u20132822 (2005).","journal-title":"Kidney Int."},{"key":"44578_CR36","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.3390\/jcm11164776","volume":"11","author":"K-M Lee","year":"2022","unstructured":"Lee, K.-M. et al. The higher the CKD stage, the higher the psychological stress in patients with CKD during COVID-19 pandemic. J. Clin. Med. 11, 4776 (2022).","journal-title":"J. Clin. Med."},{"key":"44578_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-021-02593-0","volume":"21","author":"CGN Voorend","year":"2021","unstructured":"Voorend, C. G. N. et al. Impact of the COVID-19 pandemic on symptoms of anxiety and depression and health-related quality of life in older patients with chronic kidney disease. BMC Geriatr 21, 1\u201310 (2021).","journal-title":"BMC Geriatr"},{"key":"44578_CR38","doi-asserted-by":"crossref","unstructured":"Kluzek, S., Dean, B. & Wartolowska, K. A. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ 27, (2022).","DOI":"10.1136\/bmjebm-2020-111573"},{"key":"44578_CR39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/j.ajkd.2016.02.037","volume":"68","author":"R Urquhart-Secord","year":"2016","unstructured":"Urquhart-Secord, R. et al. Patient and caregiver priorities for outcomes in hemodialysis: An international nominal group technique study. Am. J. Kidney Dis. 68, 444\u2013454 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"44578_CR40","unstructured":"Kidney Research UK. Research strategy - Kidney Research UK. https:\/\/www.kidneyresearchuk.org\/research\/research-strategy\/ (2022)."},{"key":"44578_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-020-02180-2","volume":"21","author":"PA Kalra","year":"2020","unstructured":"Kalra, P. A. et al. NIMO-CKD-UK: A real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol. 21, 1\u201310 (2020).","journal-title":"BMC Nephrol."},{"key":"44578_CR42","doi-asserted-by":"crossref","unstructured":"Greenwood, S. A. et al. The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: Study design and baseline data for a multicentre prospective double-blind randomised controlled trial. BMC Nephrol. 23, (2022).","DOI":"10.1186\/s12882-022-02896-3"},{"key":"44578_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware, J. E. & Sherbourne, C. D. The MOS 36-item short-form health survey (Sf-36): I conceptual framework and item selection. Med. Care 30, 473\u2013483 (1992).","journal-title":"Med. Care"},{"key":"44578_CR44","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp, L. B., Larocca, N. G., Muir Nash, J. & Steinberg, A. D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46, 1121\u20131123 (1989).","journal-title":"Arch. Neurol."},{"key":"44578_CR45","unstructured":"Dukes Activity Status Index (DASI) - The Kidney Quality Improvement Partnership. Think Kidneys https:\/\/www.thinkkidneys.nhs.uk\/kquip\/hub\/dukes-activity-status-index-dasi\/ (2017)."},{"key":"44578_CR46","doi-asserted-by":"publisher","unstructured":"Bohannon, R. W. & Crouch, R. 1-Minute sit-to-stand test: Systematic review of procedures, performance and clinimetric properties. J. Cardiopulm. Rehabil. Prevent. 39, 2\u20138. Preprint at https:\/\/doi.org\/10.1097\/HCR.0000000000000336 (2019).","DOI":"10.1097\/HCR.0000000000000336"},{"key":"44578_CR47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYP.0000000000000033","volume":"66","author":"RR Townsend","year":"2015","unstructured":"Townsend, R. R. et al. Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American Heart Association. Hypertension 66, 698\u2013722 (2015).","journal-title":"Hypertension"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44578-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44578-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T20:02:01Z","timestamp":1698350521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44578-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44578"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44578-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"XK has no conflicts of interest. SB has received honorarium for lectures, attended expert opinion committees and received educational funds to attend international nephrology meetings from Pharmacosmos A\/S and Vifor Pharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18401"}}